Abstract
Targeting CSCs with a DC vaccine is an innovative and rationale approach that could specifically address the most replicative and therapy-resistant subpopulation of cancer cells within a solid tumor malignancy. Patients with oral cavity squamous cell carcinoma had tumors harvested and the cells sorted for ALDH high and ALDH low cells. ALDH high cells have been shown to possess the properties of cancer stem cells. DCs were generated from the peripheral blood of patients with HNSCC and pulsed in vitro with CSC lysate. DCs generated from the peripheral blood of patients with HNSCC and pulsed with CSC lysate confer greater specific antitumor efficacy by inducing anti-CSC immunity in vitro than DCs pulsed with whole tumor or non-CSC lysate. There was greater specific lysis of ALDH high target cells (vs. ALDH low targets) by CTL co-stimulated with DCs pulsed with ALDH high tumor cells suggesting a specific anti-CSC effect with this stimulation approach. Targeting CSCs in oral cavity HNSCC tumors with a DC vaccine is feasible and demonstrates an antitumor immune response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
